Hormonal
Adiponectin, an adipocyte-secreted protein, has cardioprotective effects, and its levels are decreased in obesity, contributing to increased cardiovascular risk.
Low levels of adiponectin, a hormone produced by fat cells, are linked to higher heart disease risk. Since adiponectin levels drop in obesity, losing weight and improving metabolic health are the most effective ways to restore these protective levels and support heart health.
The adipocyte-specific secretory protein adiponectin is a particularly promising candidate in this context. Its levels are decreased in obesity. Adiponectin may mediate some of its demonstrated cardioprotective effects through its anti-inflammatory properties.
Why this rating
Supported by retrospective case-control studies and animal models, though the exact mechanism is noted as not fully elucidated and some studies used recombinant forms.
Source
Adipose Tissue, Inflammation, and Cardiovascular Disease
Anders H. Berg et al. · Circulation Research · 2005
DOI 10.1161/01.res.0000163635.62927.34
More from this paper
- Obesity drives systemic inflammation through adipose tissue secretion of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), which directly contributes to cardiovascular disease risk factors including atherosclerosis, hypertension, and insulin resistance.Good
- Weight loss, achieved through various methods including diet, exercise, and surgery, significantly decreases systemic inflammation and improves cardiovascular risk markers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →